IMMUNOPHARMACOLOGY Flashcards

1
Q

Cytotoxic Agents

A

Antimetabolites

Alkylating agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Azathioprine
MOA
Drug interactions

A

Purine antimetabolite
Prodrug of 6-mercaptopurine converted to 6-MP
- 6-MP is converted to metabolites that inhibit de novo puine nucleotide synthesis–> suppression of B and T cell function of immunoglobulin production and of IL-2 secretion.

DI: Inactivation of drugs has to do with Xanthine oxidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Glucocorticoids anti-inflammatory MOA

A

Inhibition of PLA2

Reduction of transcription of COX-2 (inflammatory cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Glucocorticoids AE

A
Short term use: HTN 
hyperglycemia 
immunosuppresion
psychotic reactions 
cognitive impairment

Long term use:
Myopathy
Cushing’s syndrome
osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glucocorticoids uses:

A
Prevent treat transplant rejection
Treat autoimmune disorders such 
- RA
- SLE
- Psoriasis
- Asthma 
- IBD
In palliative care glucocorticoids arae used to alleviate pain; nausea and fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Calcineurin inhibitors

MOA?

A
Cyclosporine
- primarily metabolized by CYP 3A4
- forms a complex w/ cyclophilin (immunophilin).
- complex inhibits calcineurin
Tacrolimus
- Binds to FK-binding protein (FKBP)
- FKBP is an immunophilin
- Tacrolimus -FKBP complex inhibits calcineurin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Calcineurin

A

Phosphatase used to activat T- Cell specific Transcription factor (NFAT)

NFAT is required for induction of cytokine genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyclosporine adverse effects

A
Nephrotoxicity*: limiting and occurs in majority of patients
tremor
HTN
Hyperglycemia
Hyperlipidemia
Osteoporosis
Hirsutism*
Gum Hyperplasia*
- Very little bone marrow toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cyclosporine USES?

A

Organ transplant
Uveitis
Rheumatoid Arthritis
Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tacrolimus Adverse Effects

A
Nephrotoxicity
Neurotoxicity*
Hyperglycemia
HTN
Hyperkalemia
GI complaints
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tacromlimus uses

A
  • transplant rejection prevention of kidneys liver and heart

- topical formulation is used for topical dermatitis and psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA of sirolimus a Proliferation signal inhibitor:

A

Sirolimus

  • structurel similar to tacrolimus
  • also binds to FKBP but does not inhibit calcineurin
  • inhibits Serine-threonine kinase mTOR*–>blocks IL-2-driven T- cell proliferation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sirolimus Adverse Effects?

A
Myelosuppresion*
Hepatotoxicity
Diarrhea
Hypertriglyceridemia
Pneumonitis
Headache
  • Nephrotoxicity is less common than w/ calcineruin inhibitors!!!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sirolimus uses

A

Renal transplantation
Sirolimus-eluting stents are used to inhibit restenosis of the blood vessels in patients with severe CAD by reducing cell proliferation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Inhibitors of Angiogenesis MOA?

A

Thalidomide

  • MOA unclear
  • inhibits synthesis of TNF-a
  • now called an immunomodulatory drug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Thalidomide indications

A

“MEL”
Erythema nodosum
Leprosum
multiple myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Cytotoxic agents

A

Antimetabolites:

  • Azathioprine
  • Methotrexate
  • Mycophenolat mofetil
  • Leflunomide

Alkylating agents:
Cyclophosphamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Azathioprine AE:

A

AE:

  • Bone marrow suppression
  • GI disturbances
  • increase in infections and malignancies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Azathioprine inactivation depends on the action of what enzyme?
What drug interaction should be avoided when taking AZA?

A

Xanthine oxidase

Allopurinol: used for control of hyperuricemia. Patients receiving allopurinol should have the dose of azathioprine reduced.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

AZAthioprine uses

A

Prevention of organ transplant rejection

severe RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Methotrexate MOA

A

At low doses is used in Rheumatic diseases to inhibit Aminoimidazolecarboxamide ribonucleotide (AICAR) transformylase.
- accumulation of AMP–> increased adenosine–> immunosuppressive (potent inhibition of inflammation by adenosine).

AICAR tranformylase catalyzes the penultimate and final step in de novo purine biosynthesis which lead to synthesis of IMP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Methotrexate AE

A
Mucosal ulceration
Hypersensitivity pneumonitis
GI ulcerations
Nausea
Leukopenia
Anemia
cirrhosis is rare
Hepatotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Methotrexate toxicity can be reduced with?

A

Leucovorin

Folic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Methotrexate CIs

A

Pregnancy

25
Q

Methotrexate uses

A
"RAPPS"
RA
Psoriasis
Psoriasis arthritis
Ankylosing spondylitis
SLE
26
Q

Mycophenolate Mofetil

MOA?

A

converted to mycophenolic acid
mycophenolic acid inhibits inosine monophosphate DH an enzyme in the de novo pathway of guanosinentriphosphate (GTP) synthesis.

This suppresses both B and T lymphocyte activation.
- lymphocytes lack enzymes necessary for the salvage pathway so they are susceptible to inhibitors of the de novo pathway

27
Q

Mycophenolate Mofetil AE

A
Nausea
vomiting 
diarrrhea 
abdominal pain
headache 
HTN
Reversible myelosuppression
28
Q

Mycophenlate mofetil uses

A

Prophylaxis of transplant rejection

SLE

29
Q

Leflunomide MOA

A

Pro drug of teriflunomide
Teriflunomide inhibits dihydroorotate DH
decreases levels of UMP
UMP is essential for the synthesis of pyrimidines

30
Q

Leflunomide AE

A
Diarrhea
Reversible alopecia
Rash
Myelosupression
Increases in aminotranferases activity
CBC and liver function tests should be monitored
Carcinogenic and teratogenic in animals
Contraindicated in pregnancy
31
Q

Leflunomide USES

A

“RaMS”
RA
SLE
Myasthenia Gravis

32
Q

Alkylating agents

A

Cyclophosphamide

  • one of the most effective immunosuppressive drugs available
  • destroys proliferating lymphoid cells
  • alkylates DNA and other molecules in resting cells
33
Q

Cyclophosphamide AE

A

Infertiltiy
Bone marrow suppression
Hemorrhagic cystitis
Rarely bladder carcinoma
Acrolein a metabolite is responsible for urinary toxicities
Long term use increases risk of infection and malignancy

34
Q

Cyclophosphamide USEs

A

treat SLE and other autoimmune diseases.

may take 3-6 months to show benefit.

35
Q

Hydrochloroquine AE

A

Hemolysis in patients w/ G6PD defeciency

Retinal damage: vision should be monitored

36
Q

Sulfasalazine structure

A

consists of sulfapyridine and 5-aminosalicylic (5-ASA) connected by diazo bond.

37
Q

Sulfasalazine MOA

A

Metabolized by bacteria in the colon to constituent moieties:

  • sulfapyridine is probably the active moiety in the tx. of rheumatoid arthritis.
  • 5-ASA moiety important in ulcerative colitis.
38
Q

Sulfasalazine AE

A
Nausea vomiting
Headache rash
Neutropenia
Thrombocytopenia is very rare
Drug induced lupus is rare
Hemolysis in patients with G6PD def.
39
Q

Sulfasalazine uses

A

Ulcerative colitis
Rheumatoid arthritis
Crohn’s disease
Ankylosing spondylitis

40
Q

Immunosuppressive Antibodies

A

Polyclonal antibodies:
- Antilymphocyte (ALG) and Antithymocyte (ATG) Antibodies
- Rho(D) Immune Globulin
Monoclonal antibodies

41
Q

Antilymphocytic globobulin (ALG) and Antithymocyte Globulin (ATG) uses

A
  • Used before stem cell transplantation to prevent graft-versus-host reaction.
  • Also use for solid organ transplantation
42
Q

Monclonal antibodies

A

TNF-a inhibitors

  • Infliximab
  • Adalimumab
  • Etanercept
43
Q

Anti-TNF-a drugs adverse effects

A
  • Cytopenias can occur: CBC should be monitored regularly
  • Serious infections are the most important potential adverse effects of TNF inhibition
  • Drugs should not be given to patients with an active infection
  • *Patients should be screened for latent TB infection before and during tx. w/ a TNF inhibitor.
  • Patients may be at risk for malignancies
44
Q

Infliximab

A
  • Chimeric monoclonal antibody
  • Binds with high affinity and specficity to humna TNF-a
  • Used in the tx. of rheumatoid arthritis; psoriatic arthirtis; ankylosing spondylitis; Crohn’s disease; and ulcerative colitis.
45
Q

Adalimumab

A

Fully humna IgG1 anti-TNF monoclonal antibody

  • Binds soluble TNF-a and prevents its interation with TNF receptors.
  • Used in the tx. of rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; Crohn;s disease and ulcerative colitis.
46
Q

Etanercept

A

Not a true Mab

  • Ligand-binding portion of a human TNF-a receptor fused to the Fc portion of human IgG1.
  • Binds to TNF-a and prevents it from interacting w/ its receptors.
47
Q

Etanercept uses

A
RA
Ankylosing spondylitis
Plaque psoriasis
polyarticular juvenile idiopathic arthritis
psoriatic arthritis
48
Q

Omalizumab
MOA?
USE?

A
  • Anti-IgE recombinant humanized monoclonal antibody
  • Binds to IgE and prevents IgE from binding to mast cells and basophils thereby preventing release of inflammatory mediators after allergen expopsure
  • Used in asthma refractory to inhaled corticoids and evidence of allergic sensitization
  • also approved for chronic urticaria
49
Q

Basiliximab

A
  • IL-2 receptor antagonist
  • Chimeric human-mouse IgG
  • Binds to the IL-2 receptor
  • Used in combination w/ ther immunosuppressants to prevent transplant rejection.
50
Q

Rituximab

A
  • Chimeric murine-human monoclonal antibody that binds to the CD20 molecule on B lymphocytes.
  • Causes depletion of circulating B cells
  • Used for tx. of non-hodgkins lymphoma and chronic lymphocytic leukemia
  • Also approved for rheumatoid arthritis.
51
Q

Anakinra
MOA
USE

A
  • IL-1 receptor antagonist
  • Recombinant version of the naturally occurring human IL-1RA that prevents IL-1 from binding to its receptor.
  • Approved for moderate to severe rheumatoid arthritis
52
Q

Abatacept
MOA?
USE?

A
  • Fusion protein that interferes w/ T-cell activation
  • Used for moderate to severe rheumatoid arthritis
  • Used for moderate to severe polyarticular juvenile idiopathic arthritis.
53
Q

Immunostimulants

A

Aldesleukin
Interferons
Bacillus Calmette-Guerin (BCG)

54
Q

Aldesleukin
MOA?
USE?

A
  • Recombinant interleukin-2 (IL-2)
  • IL-2 is lymphokine that promotes the production of cytotoxic T lymphocytes and activates NK cells.
  • Aldesleukin is indicated for the adjunctive treatment of renal cell carcinoma and malignant melanoma
55
Q

Interferons

USE?

A
Hairy cell leukemia
chronic myelogenous leukemia
malignant melanoma
Kaposi sarcoma
hep B and C infections
56
Q

Bacillus Calmette-Guerin (BCG)

A

attenuated live culture of Mycibacterium bovis

  • active against tumors MOA unknown
  • indicated for tx. and prophylaxis of carcinoma of the urinary bladder.
AE: hypersensitivity 
shock
chills 
fever
malaise
immune complex disease
57
Q

Drugs used to stop transplant rejection:

A
Glucocorticoids - prevent and treat
Tacrolimus - prevention of rejection for HLK (heartLiverKidney)
Azathioprine
Mycophenolate - prophylaxis
Basiliximab - renal transplant
58
Q

Drugs used for rheumatoid arthritis

A
Glucocorticoids
Cyclosporine
Azathioprine (SEVERE)
Methotrexate
Leflunomide
hydroxychloroquine (MILD)
sulfasalzine
Infliximab
adalimumab
Etanercept
Rituximab
Anakinra (moderate-->severe)
Abatacept (moderate to severe)
59
Q

Renal transplant drugs

A

Sirolimus

Basiliximab